MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$72,551
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from common stock subsc...
Accounts payable and accrued exp...
Amortization of discount on roya...
Others
Negative Cash Flow Breakdown
Net loss
Accounts receivable
Proceeds from notes payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-859,892
-471,218
-808,505
-2,229,040
Change in fair value of royalty liability
-
-
-
-31,324
Depreciation and amortization
11,195
-124,804
168,807
-
Amortization of discount on royalty obligation
115,334
121,774
121,774
233,888
Fair value of options issued
-
-
81,874
-
Amortization of debt discount
0
1,877
53,861
-
Other income
-
0
0
0
Impairment of intellectual property
6,374
-
-
-
Amortization of right-of-use asset
10,524
10,315
10,112
19,629
Loss on settlement of debt
-100,000
0
0
-187,514
Change in fair value of upfront purchase price liability
0
747
1,785
4,894
Change in fair value of royalty liability
0
-310,835
31,324
-
Stock based compensation
108,375
351,258
-65,813
307,159
Deposits
-
0
0
0
Imputed interest for related party advances
15,236
8,309
9,253
18,814
Deferred revenue
-
0
0
0
Warrants issued in connection with the sales representative agreement
-
4,430
-
-
Accounts receivable
76,889
59,017
143,200
51,242
Grant receivable
69,694
813,541
-915,243
153,728
Inventory
-
9,828
-
-
Prepaid expenses
-13,388
-1,064
-13,880
47,081
Depreciation and amortization
-
-
-
96,820
Accounts payable and accrued expenses
253,990
-1,532,259
868,743
950,355
Amortization of debt discount
-
-
-
52,522
Royalty liability
7,886
-
-
-
Upfront purchase price liability
-42,503
-43,684
-158,007
-155,673
Deferred revenue, grant
-
-56,590
-
-
Lease liability
-10,523
-10,316
-10,112
-19,629
Net cash used in operating activities
-432,971
-847,722
-634,447
-816,122
Payment to eidl loan
-
-
1,226
-
Payment of notes payable
-
150,000
-
-
Proceeds from sale of common stock
-
-
15,750
-
Proceeds from notes payable
-
0
0
0
Proceeds from common stock subscription and royalty agreement
500,000
1,179,110
700,000
-
Payment to economic injury disaster loan
-382
753
-
739
Payment of notes payable - related party
5,000
518,700
0
7,000
Proceeds from notes payable
75,000
-
-
-
Proceeds from notes payable - related party
85,904
205,000
95,000
847,700
Net cash provided by financing activities
505,522
699,394
810,263
839,961
Net increase (decrease) in cash
72,551
-148,328
175,816
23,839
Cash, beginning of period
139,360
287,688
88,033
-
Cash, end of period
211,911
139,360
287,688
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from common
stock subscription...
$500,000
Proceeds from notes
payable - related party
$85,904
Net cash provided by
financing activities
$505,522
Canceled cashflow
$80,382
Net increase
(decrease) in cash
$72,551
Canceled cashflow
$432,971
Proceeds from notes
payable
$75,000
Payment of notes payable
- related party
$5,000
Payment to economic
injury disaster loan
-$382
Accounts payable and
accrued expenses
$253,990
Amortization of discount on
royalty obligation
$115,334
Stock based
compensation
$108,375
Loss on settlement of
debt
-$100,000
Imputed interest for
related party advances
$15,236
Prepaid expenses
-$13,388
Depreciation and
amortization
$11,195
Amortization of right-of-use
asset
$10,524
Impairment of intellectual
property
$6,374
Net cash used in
operating activities
-$432,971
Canceled cashflow
$634,416
Net loss
-$859,892
Accounts receivable
$76,889
Grant receivable
$69,694
Upfront purchase price
liability
-$42,503
Lease liability
-$10,523
Royalty liability
$7,886
Buy us a coffee
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)